Astrazeneca Regulatory News (AZN)

Astrazeneca Information

Buy AZN Shares
Add AZN to Watchlist
Add AZN to Alert

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 12,050.00

Bid: 12,038.00

Ask: 12,040.00

Change: -106.00 (-0.87%)

Spread: 2.00 (0.017%)

Open: 12,092.00

High: 12,178.00

Low: 12,010.00

Prev. Close: 12,156.00

Last checked at -

Form 8.5 (EPT/RI)

22 May 2014 11:52

RNS Number : 8225H

Bank of America Merrill Lynch

22 May 2014

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

KEY INFORMATION

(a)	Name of exempt principal trader:

Bank of America Merrill Lynch

(b)	Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)	Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)	Date dealing undertaken:

21/05/2014

(e)	Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

2.	DEALINGS BY THE EXEMPT PRINCIPAL TRADER
(a)	Purchases and sales

Class of relevant security	Purchases/sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Common - ISIN GB0009895292	Purchase	508,806	44.545 GBP	42.68 GBP
Common - ISIN GB0009895292	Purchase	297,389	495.2 SEK	474 SEK
Common - ISIN GB0009895292	Sale	419,961	44.55 GBP	42.73 GBP
Common - ISIN GB0009895292	Sale	297,714	494.8 SEK	474.3 SEK

(b)	Derivatives transactions (other than options)
Class of relevant security		Product descriptione.g. CFD	Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
Common - ISIN GB0009895292		Swaps	Long	1	43.571 GBP
Common - ISIN GB0009895292		Swaps	Long	1	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	3	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	5	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	1	43.571 GBP
Common - ISIN GB0009895292		Swaps	Long	1	43.571 GBP
Common - ISIN GB0009895292		Swaps	Long	2	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	18	43.661 GBP
Common - ISIN GB0009895292		Swaps	Short	14	43.64 GBP
Common - ISIN GB0009895292		Swaps	Long	56	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	5	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	1	43.571 GBP
Common - ISIN GB0009895292		Swaps	Long	8	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	8	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	2	43.571 GBP
Common - ISIN GB0009895292		Swaps	Long	7	43.571 GBP
Common - ISIN GB0009895292		Swaps	Long	5	43.661 GBP
Common - ISIN GB0009895292		Swaps	Long	1	43.571 GBP
Common - ISIN GB0009895292		Swaps	Long	1	43.661 GBP
Common - ISIN GB0009895292		Swaps	Short	13,287	43.439 GBP
Common - ISIN GB0009895292		Swaps	Long	600	43.858 GBP
Common - ISIN GB0009895292		Swaps	Short	1,859	43.7 GBP
Common - ISIN GB0009895292		Swaps	Long	263	43.807 GBP
Common - ISIN GB0009895292		Swaps	Long	1,164	43.807 GBP
Common - ISIN GB0009895292		Swaps	Long	25,000	44.042 GBP
Common - ISIN GB0009895292		Swaps	Long	94	43.807 GBP
Common - ISIN GB0009895292		Swaps	Short	150	43.7 GBP
Common - ISIN GB0009895292		Swaps	Long	20	43.807 GBP
Common - ISIN GB0009895292		Swaps	Short	4,410	43.7 GBP
Common - ISIN GB0009895292		Swaps	Long	623	43.807 GBP
Common - ISIN GB0009895292		Swaps	Long	2,759	43.807 GBP
Common - ISIN GB0009895292		Swaps	Long	600	43.129 GBP
Common - ISIN GB0009895292		Swaps	Short	279	44.097 GBP
Common - ISIN GB0009895292		Swaps	Short	14,992	43.7 GBP
Common - ISIN GB0009895292		Swaps	Long	2,116	43.807 GBP
Common - ISIN GB0009895292		Swaps	Long	9,372	43.807 GBP
Common - ISIN GB0009895292		Swaps	Short	1,500	43.617 GBP
Common - ISIN GB0009895292		Swaps	Short	2,563	43.507 GBP
Common - ISIN GB0009895292		Swaps	Long	184	43.965 GBP
Common - ISIN GB0009895292		Swaps	Short	125	43.195 GBP
Common - ISIN GB0009895292		Swaps	Long	120	44.23 GBP
Common - ISIN GB0009895292		Swaps	Long	11	44.317 GBP
Common - ISIN GB0009895292		Swaps	Long	989	44.207 GBP
Common - ISIN GB0009895292		Swaps	Short	100	44.027 GBP
Common - ISIN GB0009895292		Swaps	Long	146	43.933 GBP
Common - ISIN GB0009895292		Swaps	Long	48	44.197 GBP
Common - ISIN GB0009895292		Swaps	Long	232	44.197 GBP
Common - ISIN GB0009895292		Swaps	Long	92	43.906 GBP
Common - ISIN GB0009895292		Swaps	Long	53	44.197 GBP
Common - ISIN GB0009895292		Swaps	Long	253	44.197 GBP
Common - ISIN GB0009895292		Swaps	Short	1,000	44.204 GBP
Common - ISIN GB0009895292		Swaps	Long	5,000	43.495 GBP
Common - ISIN GB0009895292		Swaps	Long	10,000	43.495 GBP
Common - ISIN GB0009895292		Swaps	Short	20,000	43.815 GBP
Common - ISIN GB0009895292		Swaps	Long	100	490.926 SEK
Common - ISIN GB0009895292		Swaps	Short	79,072	43.716 GBP
Common - ISIN GB0009895292		Swaps	Long	79,072	43.739 GBP
Common - ISIN GB0009895292		Swaps	Long	6,000	43.799 GBP
Common - ISIN GB0009895292		Swaps	Long	94,000	43.799 GBP

(c)	Options transactions in respect of existing securities
(i)	Writing, selling, purchasing or varying

Class ofrelevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number ofsecurities to which option relates	Exercise priceper unit	Typee.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)	Exercising
Class of relevant security		Product descriptione.g. call option	Number of securities	Exercise Price per unit
N/A		N/A	N/A	N/A

(d)	Other dealings (including subscribing for new securities)
Class of relevant security		Nature of dealinge.g. subscription, conversion	Details	Price per unit (if applicable)
N/A		N/A	N/A	N/A

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

3.	OTHER INFORMATION

(a)	Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

(b)	Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

Date of disclosure:	22/05/2014
Contact name:	Stacy Otieno
Telephone number:	0207 995 1335

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code'sdealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

KEY INFORMATION

(a)	Name of exempt principal trader:

Bank of America Merrill Lynch

(b)	Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Pfizer Inc

(c)	Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)	Date dealing undertaken:

21/05/2014

(e)	Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

2.	DEALINGS BY THE EXEMPT PRINCIPAL TRADER
(a)	Purchases and sales

Class of relevant security	Purchases/sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Common - ISIN US7170811035	Purchase	282	193 SEK	192.5 SEK
Common - ISIN US7170811035	Sale	282	193 SEK	192.5 SEK

(b)	Derivatives transactions (other than options)
Class of relevant security		Product descriptione.g. CFD	Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A		N/A	N/A	N/A	N/A

(c)	Options transactions in respect of existing securities
(i)	Writing, selling, purchasing or varying

Class ofrelevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number ofsecurities to which option relates	Exercise priceper unit	Typee.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)	Exercising
Class of relevant security		Product descriptione.g. call option	Number of securities	Exercise Price per unit
N/A		N/A	N/A	N/A

(d)	Other dealings (including subscribing for new securities)
Class of relevant security		Nature of dealinge.g. subscription, conversion	Details	Price per unit (if applicable)
N/A		N/A	N/A	N/A

3.	OTHER INFORMATION

(a)	Indemnity and other dealing arrangements

None

(b)	Agreements, arrangements or understandings relating to options or derivatives

None

Date of disclosure:	22/05/2014
Contact name:	Stacy Otieno
Telephone number:	0207 995 1335

This information is provided by RNS

The company news service from the London Stock Exchange

END

FERBGGDURSDBGSD

Date		Source	Headline
21st Feb 2023	11:00 am	RNS	Annual Financial Report
13th Feb 2023	2:01 pm	RNS	Director/PDMR Shareholding
13th Feb 2023	2:00 pm	RNS	Director/PDMR Shareholding
9th Feb 2023	7:00 am	RNS	Final Results
1st Feb 2023	3:00 pm	RNS	Total Voting Rights
26th Jan 2023	6:15 pm	RNS	Update on Evusheld US EUA
16th Jan 2023	7:00 am	RNS	Acquisition of Neogene Therapeutics completed
11th Jan 2023	1:00 pm	RNS	Airsupra (PT027) approved in US for asthma
9th Jan 2023	7:00 am	RNS	AstraZeneca acquire CinCor for cardiorenal asset
3rd Jan 2023	3:00 pm	RNS	Total Voting Rights
30th Dec 2022	11:00 am	RNS	Director/PDMR Shareholding
28th Dec 2022	7:05 am	RNS	Calquence Japan approval for treatment-naïve CLL
28th Dec 2022	7:00 am	RNS	Imfinzi, Imjudo approved in Japan for 3 cancers
21st Dec 2022	7:05 am	RNS	Lynparza approved in EU for prostate cancer
21st Dec 2022	7:00 am	RNS	Imfinzi approved in EU for biliary tract cancer
19th Dec 2022	7:20 am	RNS	Enhertu recommended for EU approval in HER2-low BC
19th Dec 2022	7:15 am	RNS	Enhertu approved in EU for gastric cancer
19th Dec 2022	7:10 am	RNS	Imfinzi + Imjudo recommended for approvals in EU
19th Dec 2022	7:05 am	RNS	Update on Imfinzi PEARL trial
19th Dec 2022	7:00 am	RNS	Forxiga CHMP opinion for symptomatic chronic HF
15th Dec 2022	7:00 am	RNS	Update on US review of Lynparza PROpel sNDA
8th Dec 2022	1:30 pm	RNS	Capivasertib PFS in HR-positive breast cancer
1st Dec 2022	3:00 pm	RNS	Block listing Interim Review
1st Dec 2022	3:00 pm	RNS	Total Voting Rights
30th Nov 2022	7:05 am	RNS	AstraZeneca announces sale of West Chester site
29th Nov 2022	7:00 am	RNS	AstraZeneca to acquire Neogene Therapeutics
23rd Nov 2022	3:30 pm	RNS	Director/PDMR Shareholding
14th Nov 2022	7:10 am	RNS	Enhertu recommended for EU approval in gastric
14th Nov 2022	7:05 am	RNS	Imfinzi recommended for approval in the EU for BTC
14th Nov 2022	7:00 am	RNS	Lynparza combo recommended in the EU for mCRPC
11th Nov 2022	7:00 am	RNS	Imfinzi + Imjudo approved in US for lung cancer
10th Nov 2022	7:00 am	RNS	YTD and Q3 2022 Results
9th Nov 2022	7:00 am	RNS	FDA Advisory Committee recommends PT027 in asthma
4th Nov 2022	7:00 am	RNS	Beyfortus (nirsevimab) approved in EU
1st Nov 2022	3:00 pm	RNS	Total Voting Rights
26th Oct 2022	7:00 am	RNS	Capivasertib Phase III trial met primary endpoints
25th Oct 2022	7:00 am	RNS	Update on MESSINA Phase III trial
24th Oct 2022	7:00 am	RNS	Imfinzi + Imjudo approved in advanced liver cancer
3rd Oct 2022	3:00 pm	RNS	Total Voting Rights
30th Sep 2022	10:30 am	RNS	Board Committee Changes
27th Sep 2022	7:05 am	RNS	Koselugo approved in Japan for NF1
27th Sep 2022	7:00 am	RNS	Tezspire approved in Japan for severe asthma
23rd Sep 2022	7:00 am	RNS	Ultomiris approved in EU for gMG
23rd Sep 2022	7:00 am	RNS	Ultomiris approved in EU for gMG
22nd Sep 2022	7:00 am	RNS	Lynparza approved in China for ovarian cancer
21st Sep 2022	7:00 am	RNS	Tezspire approved in the EU for severe asthma
20th Sep 2022	7:00 am	RNS	Evusheld approved in EU for COVID-19 treatment
16th Sep 2022	7:10 am	RNS	Danicopan Phase III trial met primary endpoint
16th Sep 2022	7:05 am	RNS	Evusheld positive CHMP opinion in EU
16th Sep 2022	7:00 am	RNS	Nirsevimab recommended for approval in EU by CHMP

Latest Share Chat

Astrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

Login to your account

Quickpicks are a member only feature

Login to your account